DE69519667D1 - Verfahren zur stabilisierung von duocarmycinderivaten - Google Patents

Verfahren zur stabilisierung von duocarmycinderivaten

Info

Publication number
DE69519667D1
DE69519667D1 DE69519667T DE69519667T DE69519667D1 DE 69519667 D1 DE69519667 D1 DE 69519667D1 DE 69519667 T DE69519667 T DE 69519667T DE 69519667 T DE69519667 T DE 69519667T DE 69519667 D1 DE69519667 D1 DE 69519667D1
Authority
DE
Germany
Prior art keywords
pct
derivatives
duocarmycine
stabilizing
duocarmycin derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69519667T
Other languages
English (en)
Other versions
DE69519667T2 (de
Inventor
Masashi Nakakura
Yuji Ueno
Eiji Hayakawa
Tokuyuki Kuroda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of DE69519667D1 publication Critical patent/DE69519667D1/de
Publication of DE69519667T2 publication Critical patent/DE69519667T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE69519667T 1994-05-20 1995-05-19 Verfahren zur stabilisierung von duocarmycinderivaten Expired - Fee Related DE69519667T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6106415A JPH07309761A (ja) 1994-05-20 1994-05-20 デュオカルマイシン誘導体の安定化法
PCT/JP1995/000962 WO1995031971A1 (en) 1994-05-20 1995-05-19 Method for stabilizing duocarmycin derivatives

Publications (2)

Publication Number Publication Date
DE69519667D1 true DE69519667D1 (de) 2001-01-25
DE69519667T2 DE69519667T2 (de) 2001-04-26

Family

ID=14433044

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69519667T Expired - Fee Related DE69519667T2 (de) 1994-05-20 1995-05-19 Verfahren zur stabilisierung von duocarmycinderivaten

Country Status (17)

Country Link
US (1) US5703080A (de)
EP (1) EP0754030B1 (de)
JP (1) JPH07309761A (de)
CN (1) CN1148805A (de)
AT (1) ATE198149T1 (de)
AU (1) AU2455195A (de)
BR (1) BR9507640A (de)
CA (1) CA2190635A1 (de)
CZ (1) CZ338696A3 (de)
DE (1) DE69519667T2 (de)
FI (1) FI964624A (de)
HU (1) HUT78072A (de)
NO (1) NO964813D0 (de)
NZ (1) NZ285450A (de)
PL (1) PL317229A1 (de)
SK (1) SK148496A3 (de)
WO (1) WO1995031971A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2201097A1 (en) * 1994-09-30 1996-04-11 Kyowa Hakko Kogyo Co., Ltd. Anti-tumor agents
EP1383544A4 (de) * 2001-04-09 2007-12-12 Progenics Pharm Inc Anti-cd19-immunotoxine
AU2002303929B9 (en) 2001-05-31 2007-01-25 E. R. Squibb & Sons, L.L.C. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
JP5047947B2 (ja) 2005-05-05 2012-10-10 デューク ユニバーシティ 自己免疫疾患のための抗ｃｄ１９抗体治療
NZ565378A (en) 2005-06-29 2011-03-31 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
JP5116686B2 (ja) 2005-10-26 2013-01-09 メダレックス インコーポレイテッド Ｃｃ−１０６５類似体の調製方法及び調製用化合物
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP2540741A1 (de) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
EP2097097B1 (de) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antikörper, insbesondere menschliche antikörper, die an cd22 binden und deren verwendung
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
JP2010513306A (ja) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Ｃｄ７０に結合するヒト抗体およびその使用
JP5357049B2 (ja) * 2006-12-26 2013-12-04 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の治療のためのフォスフォルアミデートアルキル化剤プロドラッグ
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
EP2121667B1 (de) 2007-02-21 2016-06-08 E. R. Squibb & Sons, L.L.C. Chemische verbinder mit einzelaminosäuren und konjugaten davon
CN101861168B (zh) 2007-05-07 2014-07-02 米迪缪尼有限公司 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
MX2010003581A (es) 2007-10-01 2010-08-02 Bristol Myers Squibb Co Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos.
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
AU2008331507A1 (en) * 2007-11-30 2009-06-11 Bristol-Myers Squibb Company Conjugates of anti-RG-1 antibodies
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
BRPI0921687A8 (pt) 2008-11-03 2022-11-08 Syntarga Bv Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
CA2743469C (en) 2008-11-12 2019-01-15 Medimmune, Llc Antibody formulation
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011047083A1 (en) 2009-10-13 2011-04-21 Oxford Biotherapeutics Ltd. Antibodies against epha10
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
PL3056203T3 (pl) 2010-04-21 2018-06-29 Syntarga B.V. Koniugaty analogów CC-1065 i łączników dwufunkcyjnych
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PL2726508T3 (pl) 2011-06-28 2017-12-29 Oxford Biotherapeutics Ltd Przeciwciała przeciwko cyklazie ADP-rybozylowej 2
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CN105377889B (zh) 2013-03-15 2020-07-17 Xencor股份有限公司 异二聚体蛋白
EP3421495A3 (de) 2013-03-15 2019-05-15 Xencor, Inc. Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
PT3055331T (pt) 2013-10-11 2021-04-05 Oxford Bio Therapeutics Ltd Anticorpos conjugados contra ly75 para o tratamento de cancro
PT3092010T (pt) 2014-01-10 2018-09-28 Synthon Biopharmaceuticals Bv Método para purificação de conjugados anticorpo-fármaco ligados por cys
ES2960619T3 (es) 2014-02-28 2024-03-05 Hangzhou Dac Biotech Co Ltd Enlazadores cargados y sus usos para la conjugación
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
CN110894240B (zh) 2014-11-26 2022-04-15 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
EP3475304B1 (de) 2016-06-28 2022-03-23 Xencor, Inc. Somatostatin-rezeptor 2 bindende heterodimere antikörper
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
PE20191034A1 (es) 2016-10-14 2019-08-05 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
CN110099682B (zh) 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
EP3706793A1 (de) 2017-11-08 2020-09-16 Xencor, Inc. Bispezifische und monospezifische antikörper unter verwendung von neuartigen anti-pd-1-sequenzen
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
MA53094A (fr) 2018-07-02 2021-05-12 Amgen Inc Protéine de liaison à l'antigène anti-steap1
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
JP2022523946A (ja) 2019-03-01 2022-04-27 ゼンコア インコーポレイテッド Ｅｎｐｐ３およびｃｄ３に結合するヘテロ二量体抗体
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
KR910014122A (ko) * 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
US5214065A (en) * 1990-06-11 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivatives
JPH0669954B2 (ja) * 1990-12-07 1994-09-07 吉富製薬株式会社 抗腫瘍組成物
EP0499130A1 (de) * 1991-02-15 1992-08-19 Kyowa Hakko Kogyo Co., Ltd. Derivate der Verbindung DC-89
JP3608802B2 (ja) * 1991-09-20 2005-01-12 第一サントリーファーマ株式会社 安定なカルシトニン医薬組成物及びその製造法

Also Published As

Publication number Publication date
CN1148805A (zh) 1997-04-30
ATE198149T1 (de) 2001-01-15
AU2455195A (en) 1995-12-18
BR9507640A (pt) 1997-08-19
FI964624A0 (fi) 1996-11-19
DE69519667T2 (de) 2001-04-26
NO964813L (no) 1996-11-13
JPH07309761A (ja) 1995-11-28
NZ285450A (en) 1997-02-24
FI964624A (fi) 1996-11-19
HU9603521D0 (en) 1997-03-28
NO964813D0 (no) 1996-11-13
EP0754030A1 (de) 1997-01-22
CA2190635A1 (en) 1995-11-30
MX9605694A (es) 1998-05-31
SK148496A3 (en) 1997-06-04
WO1995031971A1 (en) 1995-11-30
HUT78072A (hu) 1999-08-30
US5703080A (en) 1997-12-30
PL317229A1 (en) 1997-03-17
EP0754030B1 (de) 2000-12-20
CZ338696A3 (en) 1997-05-14

Similar Documents

Publication Publication Date Title
DE69519667D1 (de) Verfahren zur stabilisierung von duocarmycinderivaten
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ATE215371T1 (de) Naphthyl substituierte benzimidazolderivate als antikoagulantien
PL292095A1 (en) Pesticides and method of obtaining them
KR950700894A (ko) 탁솔 유도체(Taxol derivatives)
DK0696281T3 (da) Hidtil ukendte 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazolderivater
DE69221563D1 (de) Polyfluoralkylthiopoly(ethylimidazolium)-Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als biozide Mittel
AU699480B2 (en) 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these
KR960013370A (ko) 트리글리세리드 과다 방지 조성물
ATE247959T1 (de) Nicht peptidische g-csf mimetika
EP0340754A3 (de) Monopersulfate von Amino-(poly)percarbonsäuren
KR950700234A (ko) β-페닐이소세린 및 그외 동족체를 제조하는 방법(Method for preparing β-phenylisoserine and analogues thereof)
EA199900754A1 (ru) Способ получения замещенного тиазолидиндиона
AU5644296A (en) Novel heterocyclic chemistry
DE69330601D1 (de) Serotoninergische ergolin derivate
ATE200482T1 (de) N-substituierte azabicycloheptan-derivate als neuroleptika usw.
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
DE69531219D1 (de) Verfahren zur umwandlung von 2,4-dichlorpyridinen in 2-aryloxy-4-chlorpyridine
DE3750267D1 (de) Herstellung von Piperidinylcyclopentylheptensäure-Derivaten.
SE9001592D0 (sv) A therapeutical composition
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
KR910011258A (ko) 녹내장의 치료방법
RU94033356A (ru) Новые производные тетрагидронафталина, способ их получения, фармацевтический состав на их основе и способ его получения

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee